{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T21:33:25Z","timestamp":1774301605963,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102438","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:07:01Z","timestamp":1758600421000},"page":"102438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Bisphosphonates in Hormone-sensitive Metastatic Prostate Cancer A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2309-6175","authenticated-orcid":false,"given":"Gabriel Berlingieri","family":"Polho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-5486","authenticated-orcid":false,"given":"Adler Araujo Ribeiro","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laerte Canedo","family":"Ornelas-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3205-3799","authenticated-orcid":false,"given":"Paulo Siqueira","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felippe Lazar","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella Fernandes","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre Silva","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2480-353X","authenticated-orcid":false,"given":"Diogo Assed","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102438_bib0001","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41391-020-00296-y","article-title":"Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer","volume":"24","author":"Hussain","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102438_bib0002","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102438_bib0003","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"JNCI: J Nat Can Inst"},{"key":"10.1016\/j.clgc.2025.102438_bib0004","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102438_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100667","article-title":"Zoledronic acid in metastatic castrate-sensitive prostate cancer: a state-of-the-art review","volume":"51","author":"Damaj","year":"2025","journal-title":"Journal of Bone Oncology"},{"key":"10.1016\/j.clgc.2025.102438_bib0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","article-title":"The anti-tumour effects of zoledronic acid","volume":"3","author":"Zekri","year":"2014","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.clgc.2025.102438_bib0007","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102438_bib0008","first-page":"1","article-title":"Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial","author":"Dalla Volta","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102438_bib0009","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding Celecoxib with or without zoledronic acid for hormone-na\u00efve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial","volume":"35","author":"Mason","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102438_bib0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"22","author":"Kamba","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102438_bib0011","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102438_bib0012","first-page":"3837","article-title":"Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid\/androgen blockade trial on prostate cancer) study","volume":"33","author":"Ueno","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2025.102438_bib0013","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2025.102438_bib0014","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102438_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10585-019-09963-4","article-title":"Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer","volume":"36","author":"Wu","year":"2019","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clgc.2025.102438_bib0016","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.biopha.2013.04.006","article-title":"STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells","volume":"67","author":"Kiper","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clgc.2025.102438_bib0017","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","article-title":"Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line","volume":"44","author":"Di Salvatore","year":"2011","journal-title":"Cell Prolif"},{"key":"10.1016\/j.clgc.2025.102438_bib0018","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102438_bib0019","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102438_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e17111","article-title":"Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: A systematic literature review and meta-analysis","volume":"42","author":"Turco","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.clgc.2025.102438_bib0021","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","article-title":"Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2025.102438_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25826","article-title":"Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: A systematic review and meta-analysis","volume":"3","author":"Myint","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2025.102438_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.2467","article-title":"Bone-modifying agents in patients with high-risk metastatic castration-sensitive prostate cancer treated with abiraterone acetate","volume":"7","author":"Fukuokaya","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2025.102438_bib0024","first-page":"1","article-title":"Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data","author":"Jones","year":"2025","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.clgc.2025.102438_bib0025","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102438_bib0026","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102438_bib0027","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.clgc.2025.102438_bib0028","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines\u2020","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102438_bib0029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.critrevonc.2019.07.013","article-title":"How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials","volume":"142","author":"Santini","year":"2019","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.clgc.2025.102438_bib0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102438_bib0031","article-title":"Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study","volume":"27","author":"Khalafallah","year":"2018","journal-title":"Eur J Cancer Care"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:07:57Z","timestamp":1770671277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001387"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102438","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Bisphosphonates in Hormone-sensitive Metastatic Prostate Cancer A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102438"}}